Tanner Shae

At IPWatchdog LIVE 2026, a panel on IP litigation strategy returned to a point experienced litigators know well: most IP cases are not won at trial. Instead, the decisive work often occurs much earlier, through pre-suit diligence, early motion practice, discovery strategy, and expert challenges that shape whether a case survives long enough to reach a jury.

As artificial intelligence adoption accelerates across both commercial and government sectors, traditional contracting frameworks are being stretched beyond their limits. That tension was the focus of a panel at IPWatchdog Live 2026 today, featuring Judge Ryan T. Holte of the U.S. Court of Federal Claims; Stephanie Curcio, co-founder and CEO of NLPatent; and TJ Whittle, Legal Counsel at Anduril Industries.

On July 7, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a judgment of noninfringement in favor of Cisco Systems, Inc. in a patent infringement suit brought by Egenera, Inc. The court upheld the Massachusetts district court’s grant of summary judgment on two claims and a jury verdict on two others, concluding that Egenera failed to prove infringement of U.S. Patent No. 7,231,430 by Cisco’s Unified Computing System (UCS).

On Wednesday, June 18, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued an opinion affirming in part and vacating in part the Patent Trial and Appeal Board’s (PTAB) decision regarding Avago Technologies’ U.S. Patent No. 8,646,014. The patent, titled “Multistream Video Communication With Staggered Access Points,” addresses methods for reducing latency in video streaming systems. Specifically, it enables a video receiver to select from multiple streams the one expected to minimize latency, defined as the delay from a user’s request for content to its playback.

In a precedential decision issued on June 11, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed two Patent Trial and Appeal Board (PTAB) inter partes review (IPR) decisions invalidating Agilent Technologies’ patents related to chemically modified CRISPR guide RNAs (gRNAs).